Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Clin Transl Gastroenterol. 2018 Sep 20;9(9):183. doi: 10.1038/s41424-018-0050-3.
Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA-M2BP) is a glycomarker. The present community-based long-term follow-up study repeatedly determined the serum WFA-M2BP level and examined its short- and long-term associations with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
A total of 921 participants with antibodies against HCV seropositive, but seronegative for hepatitis B surface antigen were enrolled from seven townships in Taiwan during 1991-1992. The participants were regularly followed and their serum WFA-M2BP levels were measured at baseline and follow-up. HCC was ascertained through active follow-up and computerized data linkage with the National Cancer Registration System until December 31, 2013. Cox proportional hazards and logistic regression models were applied to estimate the magnitude of associations between serum WFA-M2BP levels and HCC.
During a median follow-up of 21.7 years, 122 new-onset HCC cases were identified. Elevated serum WFA-M2BP levels were associated with an increased risk of HCC (p < 0.001). Patients with increasing changes in serum WFA-M2BP levels, relative to their baseline levels, had a 4.36-fold risk of HCC. The areas under receiver operating curves (AUROCs) of WFA-M2BP for predicting HCC showed that the prediction efficacy was significantly higher while closer to HCC diagnosis (p = 0.024). The AUROC was 0.91 for predicting HCC within 1 year by including the predictors of age, sex, alanine aminotransferase, alpha-fetoprotein (AFP) and WFA-M2BP.
Serum WFA-M2BP level may elevate before HCC onset and is a short-term predictor of HCC among patients infected with HCV.
槐凝集素阳性人 Mac-2 结合蛋白（WFA-M2BP）是一种糖基标志物。本社区长期随访研究反复测定了血清 WFA-M2BP 水平，并研究了其与丙型肝炎病毒（HCV）相关肝细胞癌（HCC）的短期和长期关联。
1991-1992 年，从台湾的七个乡镇招募了 921 名抗 HCV 抗体阳性但乙型肝炎表面抗原阴性的参与者。参与者定期随访，并在基线和随访时测量血清 WFA-M2BP 水平。通过主动随访和与国家癌症登记系统的计算机数据链接确定 HCC，截至 2013 年 12 月 31 日。应用 Cox 比例风险和逻辑回归模型来估计血清 WFA-M2BP 水平与 HCC 之间的关联程度。
在中位随访 21.7 年期间，发现了 122 例新确诊的 HCC 病例。血清 WFA-M2BP 水平升高与 HCC 风险增加相关（p<0.001）。与基线水平相比，血清 WFA-M2BP 水平增加的患者发生 HCC 的风险增加了 4.36 倍。WFA-M2BP 预测 HCC 的接收者操作特征曲线（AUROCs）下面积表明，预测效果更高，更接近 HCC 诊断（p=0.024）。通过纳入年龄、性别、丙氨酸氨基转移酶、甲胎蛋白（AFP）和 WFA-M2BP 的预测因子，WFA-M2BP 对预测 HCC 1 年内的 AUC 为 0.91。
血清 WFA-M2BP 水平可能在 HCC 发病前升高，是 HCV 感染患者 HCC 的短期预测指标。
